Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to ...
J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment ...
The startup is built around technology it claims can help get after known, but undruggable cancer targets and design ...
AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...
Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have ...
The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a ...
On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall ...
The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...
The breakup, which will separate Aetna and Caremark from CVS’ retail pharmacies, is an indictment of the dogma that bigger is ...
Explore how integrated scenario modeling helps pharma leaders navigate pricing uncertainty and the complexity of global ...
The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results